source
- Merck barred from making subcutaneous Keytruda in 8 European countriesWith the patent court siding with Halozyme, Merck faces restrictions on a product that won approval in Europe last year.BioSpace · 12d ago↗ source
- Cerevance's solengepras cuts OFF time in phase 3 Parkinson's trialCerevance reported that its oral non‑dopaminergic therapy, solengepras, produced meaningful improvements in both motor and non‑motor symptoms in a phase 3 Parkinson's disease study, rescuing the ca…